Spero therapeutics to present at the 5th annual evercore isi healthconx conference

Cambridge, mass., nov. 22, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) (spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that ankit mahadevia, m.d., president and chief executive officer of spero therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5th annual evercore isi healthconx conference, which is taking place virtually, november 29, 2022 through december 1, 2022. details for the fireside chat are as follows:
SPRO Ratings Summary
SPRO Quant Ranking